概括
后静止力增强 (PESP) 和上腺素输注可以预测冠状动脉疾病患者的 reduced ejection fraction 的结果. 较大的射出分数增大表明医疗或手术治疗的短期预后更好.
科学领域:
- 心脏病学 心脏病学
- 心血管生理学心血管生理学
背景情况:
- 冠状动脉疾病 (CAD) 患者的射出分数减少 (EF <0.50) 的预后较差.
- 后创思托力强化 (PESP) 和1-上腺素输注可以增强左心室 (LV) 功能.
研究的目的:
- 为了将LV功能增强的幅度与减少EF的CAD患者的短期预后相关联.
- 为了确定评估收缩储备的首选无otropic刺激.
主要方法:
- 在56名CAD患者中,心室内膜壁运动的评估,EF<0.50.
- 42名患者接受了PESP,14名患者接受了1-上腺素输液.
- 在医疗或手术治疗后,患者被跟踪平均11.7-14.3个月.
主要成果:
- 与表现不佳的患者相比,表现良好的患者的平均EF增加显著增加.
- EF增加≥0.10预测了统计学上更好的预后.
- PESP表现出比1 - 上腺素输注更大的收缩性增强.
结论:
- 内热刺激 (PESP或上腺素) 可以识别具有更大的收缩储备和更好的短期预后的患者.
- 由于易于使用和优异的收缩性增强,PESP是首选的无otropic刺激剂.
相关概念视频
Regulation of Stroke Volume
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


